{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:52:22Z","timestamp":1775065942370,"version":"3.50.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001336","name":"University of the Witwatersrand, Johannesburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic condition with complete age-dependent penetrance, variable expressivity and a global prevalence of \u223c1\/3,000. It is characteriszed by numerous caf\u00e9-au-lait macules, skin freckling in the inguinal or axillary regions, Lisch nodules of the iris, optic gliomas, neurofibromas, and tumour predisposition. The diagnostic testing strategy for NF1 includes testing for DNA single nucleotide variants (SNVs), copy number variants (CNVs) as well as RNA analysis for deep intronic and splice variants, which can cumulatively identify the causative variant in 95% of patients. In the present study, NF1 patients were screened using a next-generation sequencing (NGS) assay targeting <jats:italic>NF1<\/jats:italic> exons and intron\/exon boundaries for SNV and <jats:italic>NF1<\/jats:italic> multiple ligation-dependent probe amplification (MLPA) analysis for CNV detection. Twenty-six unrelated Southern African patients clinically suspected of having NF1, based on the clinical diagnostic criteria developed by the National Institute of Health (NIH), were included in the current study. A detection rate of 58% (15\/26) was obtained, with SNVs identified in 80% (12\/15) using a targeted gene panel and <jats:italic>NF1<\/jats:italic> gene deletion in 20% (3\/15) identified using MLPA. Ten patients (38%) had no variants identified, although they met NF1 diagnostic criteria. One VUS was identified in this study in a patient that met NF1 diagnostic criteria, however there was no sufficient information to classify variant as pathogenic. The clinical features of Southern African patients with NF1 are similar to that of the known NF1 phenotype, with the exception of a lower frequency of plexiform neurofibromas and a higher frequency of developmental\/intellectual disability compared to other cohorts. This is the first clinical and molecular characterisation of a Southern African ancestry NF1 cohort using both next-generation sequencing and MLPA analysis. A significant number of patients remained without a diagnosis following DNA-level testing. The current study offers a potential molecular testing strategy for our low resource environment that could benefit a significant proportion of patients who previously only received a clinical diagnosis without molecular confirmation.<\/jats:p>","DOI":"10.3389\/fgene.2024.1331278","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:51:40Z","timestamp":1711428700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Mutation analysis and clinical profile of South African patients with Neurofibromatosis type 1 (NF1) phenotype"],"prefix":"10.3389","volume":"15","author":[{"given":"Maria Mabyalwa","family":"Mudau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwyn","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarice","family":"Smal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Feben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engela","family":"Honey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Carstens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1631","article-title":"Mutational spectrum of NF1 gene in 24 unrelated Egyptian families with neurofibromatosis type 1","author":"Abdel-Aziz","year":"2021","journal-title":"Mol. Genet. genomic Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/humu.23626","article-title":"Recommendations for interpreting the loss of function PVS1 ACMG\/AMP variant criterion","volume":"39","author":"Abou Tayoun","year":"2018","journal-title":"Hum. Mutat."},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-444-62702-5.00004-4","article-title":"Neurofibromatosis type 1","volume":"132","author":"Anderson","year":"2015","journal-title":"Handb. Clin. Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E2365","DOI":"10.3390\/cells9112365","article-title":"Neurofibromin structure, functions and regulation","volume":"9","author":"Bergoug","year":"2020","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/humu.22152","article-title":"Review and update of SPRED1 mutations causing Legius syndrome","volume":"33","author":"Brems","year":"2012","journal-title":"Hum. Mutat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/cge.13649","article-title":"Mutational spectrum by phenotype: panel-based NGS testing of patients with clinical suspicion of RASopathy and children with multiple caf\u00e9-au-lait macules","volume":"97","author":"Castellanos","year":"2020","journal-title":"Clin. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/B978-0-444-64076-5.00051-X","article-title":"Neurofibromatosis type 1","volume":"148","author":"Cimino","year":"2018","journal-title":"Neurogenetics, Part II"},{"key":"B8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/(sici)1096-8628(19991203)87:4<317::aid-ajmg7>3.0.co;2-x","article-title":"Neurofibromatosis type 1 growth charts","volume":"87","author":"Clementi","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/(SICI)1098-1004(1997)9:5<458::AID-HUMU13>3.0.CO;2-1","article-title":"Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1?","volume":"9","author":"Cnossen","year":"1997","journal-title":"Hum. Mutat."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40246-023-00451-1","article-title":"SpliceAI-visual: a free online tool to improve SpliceAI splicing variant interpretation","volume":"17","author":"de Sainte Agathe","year":"2023","journal-title":"Hum. Genomics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ebiom.2016.04.005","article-title":"Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only","volume":"7","author":"Evans","year":"2016","journal-title":"EBioMedicine"},{"key":"B12","article-title":"Neurofibromatosis 1","volume-title":"GeneReviews\u00ae. Seattle (WA)","author":"Friedman","year":""},{"key":"B13","article-title":"Neurofibromatosis 1","volume-title":"GeneReviews\u00ae. Seattle (WA)","author":"Friedman","year":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/gim.2018.3","article-title":"ClinGen\u2019s RASopathy Expert Panel consensus methods for variant interpretation","volume":"20","author":"Gelb","year":"2018","journal-title":"Genet. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-genet-112414-054639","article-title":"Nonsense-mediated mRNA decay: degradation of defective transcripts is only part of the story","volume":"49","author":"He","year":"2015","journal-title":"Annu. Rev. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/jhg.2015.6","article-title":"NF1 single and multi-exons copy number variations in neurofibromatosis type 1","volume":"60","author":"Imbard","year":"2015","journal-title":"J. Hum. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clindermatol.2020.03.010","article-title":"RASopathies","volume":"38","author":"Jafry","year":"2020","journal-title":"Clin. Dermatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13041-019-0517-5","article-title":"The impact of RASopathy-associated mutations on CNS development in mice and humans","volume":"12","author":"Kang","year":"2019","journal-title":"Mol. Brain"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00439-021-02363-3","article-title":"Classification of NF1 microdeletions and its importance for establishing genotype\/phenotype correlations in patients with NF1 microdeletions","volume":"140","author":"Kehrer-Sawatzki","year":"2021","journal-title":"Hum. Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00439-021-02410-z","article-title":"Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants","volume":"141","author":"Kehrer-Sawatzki","year":"2022","journal-title":"Hum. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/humu.23929","article-title":"Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1","volume":"41","author":"Koczkowska","year":"2020","journal-title":"Hum. Mutat."},{"key":"B22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1242\/jcs.181008","article-title":"Nonsense-mediated mRNA decay in humans at a glance","volume":"129","author":"Kurosaki","year":"2016","journal-title":"J. Cell Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12881-018-0615-8","article-title":"Clinical characteristics and spectrum of NF1 mutations in 12 unrelated Chinese families with neurofibromatosis type 1","volume":"19","author":"Mao","year":"2018","journal-title":"BMC Med. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"104847","DOI":"10.1016\/j.ejmg.2023.104847","article-title":"Reassessment of the NF1 variants of unknown significance found during the 20-year activity of a genetics diagnostic laboratory","volume":"66","author":"Martorana","year":"2023","journal-title":"Eur. J. Med. Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jmg.2009.075937","article-title":"Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions","volume":"47","author":"Mautner","year":"2010","journal-title":"J. Med. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-642-32864-0_12","article-title":"NF1 germline and somatic mosaicism","author":"Messiaen","year":"2012","journal-title":"Neurofibromatosis Type 1 Mol. Cell. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12687-023-00674-8","article-title":"A feasible molecular diagnostic strategy for rare genetic disorders within resource-constrained environments","volume":"15","author":"Mudau","year":"2023","journal-title":"J. Community Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/088307389300800421","article-title":"Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic","volume":"8","author":"North","year":"1993","journal-title":"J. Child Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1365-4632.2005.02386.x","article-title":"Clinicopathological study of neurofibromatosis type 1: an experience in Nigeria","volume":"44","author":"Odebode","year":"2005","journal-title":"Int. J. Dermatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.3390\/cancers13122963","article-title":"Severe phenotype in patients with large deletions of NF1","volume":"13","author":"Pacot","year":"2021","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E1506","DOI":"10.1002\/humu.21271","article-title":"NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype","volume":"31","author":"Pasmant","year":"2010","journal-title":"Hum. Mutat."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1002\/humu.20826","article-title":"Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations","volume":"29","author":"Pros","year":"2008","journal-title":"Hum. Mutat."},{"key":"B37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/08830738060210011501","article-title":"Clinical phenotype of South African children with neurofibromatosis 1","volume":"21","author":"Ramanjam","year":"2006","journal-title":"J. Child Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med. Official J. Am. Coll. Med. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/gcc.22997","article-title":"Recurrent NF1 gene variants and their genotype\/phenotype correlations in patients with Neurofibromatosis type I","volume":"61","author":"Riva","year":"2022","journal-title":"Genes, Chromosomes Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","article-title":"Variant review with the integrative genomics viewer","volume":"77","author":"Robinson","year":"2017","journal-title":"Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/humu.22392","article-title":"NF1 molecular characterization and neurofibromatosis type I genotype\u2013phenotype correlation: the French experience","volume":"34","author":"Sabbagh","year":"2013","journal-title":"Hum. Mutat."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s00381-011-1554-2","article-title":"Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas?","volume":"27","author":"Schindera","year":"2011","journal-title":"Child\u2019s Nerv. Syst. ChNS Official J. Int. Soc. Pediatr. Neurosurg."},{"key":"B43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.48327\/mtsi.v2i2.2022.247","article-title":"Clinical aspects of neurofibromatosis type 1 seen in the department of dermatology at university hospital antananarivo, Madagascar","volume":"2","author":"Sendrasoa","year":"2022","journal-title":"Med. Trop. Sante Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/0883073812446310","article-title":"Height assessments in children with neurofibromatosis type 1","volume":"28","author":"Soucy","year":"2013","journal-title":"J. child neurology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/humu.10212","article-title":"Human gene mutation database (HGMD): 2003 update","volume":"21","author":"Stenson","year":"2003","journal-title":"Hum. Mutat."},{"key":"B46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1399-0004.2006.00576.x","article-title":"Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype","volume":"69","author":"Stevenson","year":"2006","journal-title":"Clin. Genet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.1074\/jbc.AW118.003232","article-title":"Mechanism of premature translation termination on a sense codon","volume":"293","author":"Svidritskiy","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-a","article-title":"Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/dmcn.13526","article-title":"Neurodevelopmental disorders in children with neurofibromatosis type 1","volume":"59","author":"Vogel","year":"2017","journal-title":"Dev. Med. Child Neurology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1177\/0883073818786807","article-title":"Height growth impairment in children with neurofibromatosis type 1 is characterized by decreased pubertal growth velocity in both sexes","volume":"33","author":"Zessis","year":"2018","journal-title":"J. Child Neurology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"603195","DOI":"10.3389\/fgene.2021.603195","article-title":"Molecular diagnosis of neurofibromatosis by multigene panel testing","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Genet."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1331278\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:51:46Z","timestamp":1711428706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1331278\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":51,"alternative-id":["10.3389\/fgene.2024.1331278"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2024.1331278","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"article-number":"1331278"}}